Skip to content

Evidence Hub

Blog
Jan 13, 2022

A 2021 round-up of 10 articles, media and events about Replica and its solutions

By Replica Analytics staff Posted On: January 13th, 2022
Start Reading
Blog
Jan 4, 2022

Why we acquired synthetic data pioneer Replica Analytics

The potential for real-world evidence (RWE) to improve patient lives and better protect ...
Start Reading
Blog
Dec 22, 2021

What I learned from former FDA leaders during Aetion’s RWE Summit

Aetion hosted our annual RWE Summit in New York last month, and I am still inspired by ...
Start Reading
Blog
Dec 22, 2021

8 Really Good Reasons to Work at Replica Analytics

By Replica Analytics staff Posted On: December 22nd, 2021 At Replica Analytics, we’re ...
Start Reading
Blog
Dec 21, 2021

Research spotlight: Using RWE to characterize prescription opioid dispensing patterns after surgical abortion

Over 800,000 abortions occur annually in the United States, the majority of which are ...
Start Reading
Blog
Dec 21, 2021

Predictions and resolutions for synthetic data

By Dr. Khaled El Emam Posted On: December 21st, 2021
Start Reading
Blog
Dec 16, 2021

Discover AI publishes 7 key use cases for synthetic data in the pharmaceutical industry

By Replica Analytics staff Posted On: December 16, 2021
Start Reading
Blog
Dec 2, 2021

Norwegian data protection authority strongly recommends synthetic data for software testing

By Dr. Khaled El Emam Posted On: December 2nd, 2021
Start Reading
Blog
Nov 18, 2021

What industry can learn from RWE demonstration projects

As global regulatory and health technology assessment (HTA) bodies continue to iterate on ...
Start Reading
Blog
Nov 12, 2021

RWE guidance watch: EMA real world evidence guidance on registry-based studies

UPDATE: As of November 2021, EMA has now issued its final guideline on registry-based ...
Start Reading
Blog
Nov 9, 2021

New Gartner survey suggests synthetic data is the future of data sharing

By Dr. Khaled El Emam Posted On: November 9th, 2021
Start Reading
Blog
Oct 29, 2021

COVID-19 vaccine rollout shows real-world evidence was ready for the spotlight

Just 10 months since administration of the first COVID-19 vaccine dose, hundreds of ...
Start Reading
Blog
Sep 30, 2021

Join primary and real-world data to generate patient-relevant RWE across the product lifecycle: Q&A with Dr. Javier Jimenez of Syneos Health

Understanding how medical interventions impact patients has always been a top priority ...
Start Reading
Blog
Sep 17, 2021

Ten Recommendations for Regulating Non-identifiable Data

There is considerable activity today in regulatory development and updates around the ...
Start Reading
Blog
Sep 9, 2021

ICPE Research Spotlight 2021: Part II: Forging methods to advance principled database epidemiology

This year at ICPE All Access, Aetion’s scientific research was represented across ...
Start Reading
Blog
Aug 26, 2021

ICPE Research Spotlight 2021: Part I: Findings from Aetion-FDA research collaboration to advance understanding of COVID-19 with RWE

This year at ICPE All Access, Aetion’s scientific research is represented across ...
Start Reading
Blog
Aug 26, 2021

RWE to inform value decision-making: Learnings from ICER’s 24-month reassessment pilot

In its 2020 Value Assessment Framework, the Institute of Clinical and Economic Review ...
Start Reading
Blog
Aug 12, 2021

Patient voice in RWE: Generating evidence that will impact payer and HTA decision-making

With the rise of patient-centered medicine and accelerated approvals, health technology ...
Start Reading
Blog
Aug 5, 2021

RWE Guidance Watch: IMPACT HTA publishes recommendations on the use of RWE in HTA

As researchers await comprehensive guidance on the use of real-world evidence (RWE)—and ...
Start Reading
Blog
Jul 29, 2021

An update on efforts to standardize and democratize RWE: Q&A with Dr. Nirosha Mahendraratnam Lederer

As real-world evidence (RWE) adoption continues to ramp up across health care, ...
Start Reading
Blog
Jul 22, 2021

Research spotlight: Gilead Sciences and Aetion use RWE to assess the comparative effectiveness of remdesivir for COVID-19

As COVID-19 continues to evolve, frontline health care workers are eager for real-world ...
Start Reading
Blog
Jul 8, 2021

Using RWE to characterize diseases as novel treatments become available: Q&A with Dr. Maria Schneeweiss

As novel therapies come to market, especially in disease areas that aren’t as well ...
Start Reading
Blog
Jul 2, 2021

Research spotlight: Using RWD sources to describe the patient burden of a poorly understood rare disease

This month, Aetion and Boehringer Ingelheim published two co-authored papers which ...
Start Reading
Blog
Jun 10, 2021

Research spotlight: Organized structure of RWE best practices

In the last five to 10 years, stakeholders from around the globe have launched ...
Start Reading